Search

Displaying results 4271 - 4280 of 10000 in total
  1. Drug

    Tertomotide

    go.drugbank.com/drugs/DB12747
    Investigational

    Tertomotide is under investigation in clinical trial NCT01223209 (A Study, Combination, Immunologic Study of LTX-315 as adjunct to tertomotide in Patients Following Curative Surgery for Carcinoma).

  2. Drug

    D-Tryptophan

    go.drugbank.com/drugs/DB03225
    Experimental

    Tryptophan is one of the 20 standard amino acids, as well as an essential amino acid in the human diet. It is encoded in the standard genetic code as the codon UGG. … The distinguishing structural characteristic of tryptophan is that it contains an indole functional group. It is an essential amino acid as defined by its growth effects on rats.

  3. Drug

    Bismuth subcitrate potassium

    go.drugbank.com/drugs/DB09275
    ApprovedInvestigational

    A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).

  4. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    Despite the lack of controlled trials, barbexaclone was used widely in Turkey until it was discontinued in 2009. … These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials.

  5. Drug

    p-Fluorofentanyl

    go.drugbank.com/drugs/DB09177
    ExperimentalIllicit

    p-Fluorofentanyl is an opioid analgesic being an analogue of fentanyl developed by Janssen Pharmaceutica in the 1960s. p-Fluorofentanyl was sold briefly on the US black market in the early 1980s, before … they appeared. p-Fluorofentanyl is made with the same synthetic route as fentanyl, but by substituting para-fluoroaniline for aniline in the synthesis.

  6. Drug

    MB-07803

    go.drugbank.com/drugs/DB05053
    Investigational

    It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.

  7. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp).

  8. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    mutations in the kinase domain of FGFR. … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  9. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  10. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    autoimmune hemolysis that are often observed in CHAPLE disease. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.